ArticleEJNMMI research2018
External radiation exposure, excretion, and effective half-life in
Article in EJNMMI research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Final overall survival and safety analyses of the phase III PSMAfore trial of [Annals of oncology : official journal of the European Society for Medical Oncology · 2025Trial
- Radiation safety management for stereotactic body radiation therapy incidentally concurrent with Pluvicto® (Lu-177) therapy - a case report.Journal of applied clinical medical physics · 2026Article
- Quantitative SPECT imaging for predicting therapeutic response to lutetium-177 DOTATATE in neuroendocrine tumors.Annals of nuclear medicine · 2026Article
- Clinical value of per-treatment whole-body single-time-point automated dosimetry for [European journal of nuclear medicine and molecular imaging · 2026Article
- Monitoring Cytogenetic Effects in Peripheral Blood Lymphocytes of Thyroid Cancer Patients Receiving Radioiodine Treatment.International journal of molecular sciences · 2026Article
- Dosimetry of [EJNMMI research · 2026Article
- 177Lu-based radioligand therapy: A retrospective multicenter analysis to calculate the effective half-life and follow-up dose for the public.Nuklearmedizin. Nuclear medicine · 2026Article
- Low Radioactivity Levels in Blood Samples After Targeted Radionuclide Therapy: Minimal Radiation Exposure of Healthcare Staff.Biomedicines · 2026Article
- Radiopharmaceuticals: Status, Regulatory Landscape and Future Perspective.AAPS PharmSciTech · 2026Review
- Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.Signal transduction and targeted therapy · 2025Article
- Clinical evaluation of fluorine-urethane resin-coated films for preventing and managingAnnals of nuclear medicine · 2025Article
- First-in-Human Phase 0 Study of AB001, a Prostate-Specific Membrane Antigen-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2025Article
- Radioactivity levels in the saliva of patients undergoing targeted radioligand therapy with [Clinical oral investigations · 2025Article
- Efficacy of innovative systemic treatments in combination with radiotherapy for bone metastases: a GEMO (the European Study Group of Bone Metastases) state of the art.Cancer metastasis reviews · 2025Review
- Radiation safety and dialysate analysis in hemodialysis following Lu-177-PSMA-617 therapy: A case report.Radiology case reports · 2025Article
- Targeted radioligand therapy: physics and biology, internal dosimetry and other practical aspects duringTheranostics · 2025Review
- Development of a homotrimeric PSMA radioligand based on the NOTI chelating platform.EJNMMI radiopharmacy and chemistry · 2024Article
- Feasibility ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024Article
- Radiation exposure and protection advice after [EJNMMI research · 2024Article
- Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlightingEJNMMI physics · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific membrane antigen (PSMA)-targeted therapy with
resultsIn total, 50 patients with mCRPC and treated with
conclusionsIn terms of the radiation exposure to the public,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.